Search for:

In brief

The AEMPS has published new indications on the adaptation of veterinary medicinal products to the content of Regulation (EU) 2019/6, which establishes a period of five years for veterinary medicinal products authorised under the previous legislation to adapt to the provisions of the new Regulation. For this reason, the QRD has been adapted to version 9.0 on the summaries of product characteristics, package leaflet and labelling of veterinary medicinal products. In this regard, the AEMPS hereby informs applicants of certain matters to be taken into account for those medicinal products that are subject to this change.

In more detail

Regulation (EU) 2019/6, of 11 December 2018, on veterinary medicinal products (hereinafter, “Regulation“) gives a period of five years to adapt veterinary medicinal products authorised under the previous Directive 2001/82/EC to the current Regulation. For this purpose, the Quality Review of Documents (hereinafter, “QRD“) has to be adapted to version 9.0, which includes the summaries of product characteristics of veterinary medicinal products, the package leaflet and the labelling of veterinary medicinal products. It is also worth mentioning that in October 2022, the Spanish Agency of Medicines and Health Products (hereinafter, “AEMPS“) already issued an information note on the fees for the variation procedure, which can be consulted via this link.

It is worth mentioning that version 9 of the QRD model is already adapted to the requirements established in the Regulation, and its content includes, among other features, a new order structure of the labelling and package leaflet of the veterinary medicinal product, in addition to a simplification of the external labelling, as well as a new section on restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products, and a greater flexibility on the content of various sections. Detailed information on the current QRD model is available via this link.

In this regard, the AEMPS has adopted a series of measures with the aim of facilitating the development and harmonisation of these new procedures, applicable both at national level and in centralised procedures. The different actions include the following:

  1. Flexibility in the implementation time of the change

A period of up to twelve months has been established for the implementation of changes to the packaging material of those medicinal products that have been authorised on a national basis, irrespective of the procedure used for such approval. This requires that the variation is only an individual modification of type G.I.18, i.e., not applied for as a grouping. In case the modification is applied for as a group, the implementation date shall be the one set out in the authorisation resolution of the relevant group. Likewise, if further variations concerning the texts of the medicinal product are authorised within the twelve-month period, the dates to be taken into account for their implementation will be those set out in their resolutions, and version 9 of the QRD must also be used.

It is also necessary for the holder of the medicinal product to use the electronic G.I.18 variation application form to indicate that all changes will be implemented before the end of the twelve-month period.

  1. Reduction of the administrative burden

Applicants requesting the amendments should check that the template of the new QRD version has been correctly used to adapt all the texts attached to the application and those submitted in response to the assessment carried out by the AEMPS.

In short, this new development is particularly relevant for all those companies whose activity is focused on the marketing of veterinary medicinal products and who intend to carry out their activity in Spain. In this regard, please contact our team of experts at Baker McKenzie for further advice on all the procedures related to this new AEMPS development.


Montserrat has extensive experience in pharmaceutical and health law, as well as in compliance, contract law, licensing, competition law and acquisitions in the pharmaceutical sector. She is the coordinator of the healthcare practice in the Barcelona office.
She assists healthcare companies throughout the life cycle of healthcare products (drugs, IVD and medical devices, combination products, cosmetics and food supplements), from R&D to commercialization and more specifically in the areas of clinical trials (agreements, regulatory procedures, processing of personal data), market access (pricing and reimbursement), products and companies regulations (MA/CE-marking, vigilances, required licenses, product classification, labelling), commercial relations between healthcare industries (distribution, (co)promotion, manufacturing, supply, licensing, partnership agreements), relations with healthcare professionals and/or patients including compliance (anti-gift and transparency laws); communication and advertising, e-health (connected devices, telemedicine, hosting of health data) and product liability. Her practice encompasses both advisory and litigation matters.
She also has considerable experience in the drafting of codes of professional ethics and conducting compliance audits, and advising on advertising and promotion of medicines and medical devices, including via the internet, online advertising and social media. Montserrat advises on a wide range of agreements related to the pharmaceutical industry, such as license and distribution agreements, clinical trial agreements, and supply and manufacturing agreements.

Write A Comment